KR20240017910A - 인지 향상제로서 line-1 억제제 - Google Patents

인지 향상제로서 line-1 억제제 Download PDF

Info

Publication number
KR20240017910A
KR20240017910A KR1020247000214A KR20247000214A KR20240017910A KR 20240017910 A KR20240017910 A KR 20240017910A KR 1020247000214 A KR1020247000214 A KR 1020247000214A KR 20247000214 A KR20247000214 A KR 20247000214A KR 20240017910 A KR20240017910 A KR 20240017910A
Authority
KR
South Korea
Prior art keywords
line
inhibitor
cognitive
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000214A
Other languages
English (en)
Korean (ko)
Inventor
에카르트 웨버
앤드류 새틀린
Original Assignee
트랜스포손 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트랜스포손 테라퓨틱스, 인코포레이티드 filed Critical 트랜스포손 테라퓨틱스, 인코포레이티드
Publication of KR20240017910A publication Critical patent/KR20240017910A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247000214A 2021-06-04 2022-06-03 인지 향상제로서 line-1 억제제 Pending KR20240017910A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197015P 2021-06-04 2021-06-04
US63/197,015 2021-06-04
PCT/US2022/032120 WO2022256625A1 (en) 2021-06-04 2022-06-03 Line-1 inhibitors as cognitive enhancers

Publications (1)

Publication Number Publication Date
KR20240017910A true KR20240017910A (ko) 2024-02-08

Family

ID=84323626

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000214A Pending KR20240017910A (ko) 2021-06-04 2022-06-03 인지 향상제로서 line-1 억제제

Country Status (10)

Country Link
US (1) US20240285664A1 (https=)
EP (1) EP4346835A4 (https=)
JP (1) JP2024520132A (https=)
KR (1) KR20240017910A (https=)
CN (1) CN117813096A (https=)
AU (1) AU2022283915A1 (https=)
CA (1) CA3221190A1 (https=)
IL (1) IL309036A (https=)
MX (1) MX2023014381A (https=)
WO (1) WO2022256625A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250170158A1 (en) * 2022-02-22 2025-05-29 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
WO2024107850A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
EP3914604B1 (en) * 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
KR20230107543A (ko) * 2020-09-23 2023-07-17 트랜스포손 테라퓨틱스, 인코포레이티드 질병을 치료하기 위한 line-1 억제제

Also Published As

Publication number Publication date
MX2023014381A (es) 2023-12-15
CN117813096A (zh) 2024-04-02
EP4346835A4 (en) 2025-04-16
IL309036A (en) 2024-02-01
EP4346835A1 (en) 2024-04-10
WO2022256625A1 (en) 2022-12-08
AU2022283915A1 (en) 2024-01-18
US20240285664A1 (en) 2024-08-29
JP2024520132A (ja) 2024-05-21
CA3221190A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
KR20240017910A (ko) 인지 향상제로서 line-1 억제제
AU2015371255B2 (en) Fused pyrimidine compounds for the treatment of HIV
JP2024020274A (ja) ＳＡＲＳ－ＣｏＶ－２感染の治療における置換アミノプロピオン酸化合物の使用
AU2025263907A1 (en) Methods of treating and preventing graft versus host disease
US20100286188A1 (en) Means for improving cognitive functions and memory based on hydrogenated pyrido(4,3-b)indoles (variants), pharmacological means based thereon and method for the use thereof
JP2024511973A (ja) Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤
CN101990434A (zh) 用于治疗沙粒病毒感染的抗病毒药物
KR20180117710A (ko) 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
TWI745271B (zh) 全身紅斑性狼瘡之治療
MD3570834T2 (ro) Inhibitori biciclici ai histon deacetilazei
US20250235426A1 (en) Pharmaceutical Combination and Use Thereof
ES2655291T3 (es) Uso de cladribina para tratar neuromielitis óptica
DK2555775T3 (en) Combination Compositions of Adenosine A1 Agonists and Carbonic Anhydrase Inhibitors to Reduce Intraocular Pressure
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
TW201736391A (zh) 作為人類鼻病毒抑制劑之炔基核苷類似物
JP2022527386A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
US20250041267A1 (en) Treatement for cryopyrin associated periodic syndromes (caps)
EP3782620B1 (en) Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia
CA3119395C (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
EP3758697B1 (en) Novel antimycobacterial heterocyclic amides
EP2626073A1 (en) Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
KR20180100646A (ko) 자폐 스펙트럼 장애의 예방 또는 치료제
WO2026081738A1 (zh) PI3Kα突变选择性抑制剂的用途
OA21831A (en) LINE-1 inhibitors to treat CNS and systemic diseases.
CA3119395A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250602

Comment text: Request for Examination of Application